- Home
- SMBK vs RGNX Comparison
SMBK vs RGNX Comparison
Compare SMBK & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SMBK | RGNX |
|---|---|---|
| Founded | N/A | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 636.5M | 661.2M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | SMBK | RGNX |
|---|---|---|
| Price | $38.02 | $14.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $38.63 | $30.78 |
| AVG Volume (30 Days) | 109.8K | ★ 702.7K |
| Earning Date | 01-20-2026 | 11-06-2025 |
| Dividend Yield | ★ 0.84% | N/A |
| EPS Growth | ★ 41.99 | N/A |
| EPS | ★ 2.74 | N/A |
| Revenue | ★ $188,204,000.00 | $161,318,000.00 |
| Revenue This Year | $22.00 | $132.80 |
| Revenue Next Year | $9.67 | $45.32 |
| P/E Ratio | $13.97 | ★ N/A |
| Revenue Growth | 18.22 | ★ 91.30 |
| 52 Week Low | $26.31 | $5.04 |
| 52 Week High | $40.08 | $15.41 |
Technical Indicators
Market Signals| Indicator | SMBK | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 52.34 | 60.75 |
| Support Level | $38.40 | $12.91 |
| Resistance Level | $39.86 | $15.41 |
| Average True Range (ATR) | 0.89 | 0.93 |
| MACD | -0.11 | 0.10 |
| Stochastic Oscillator | 34.24 | 66.07 |
Price Performance
Historical ComparisonAbout SMBK SmartFinancial Inc.
SmartFinancial Inc operates as a bank holding company for SmartBank. It offers various banking and financial services to individuals and corporate customers. The principal business of the Bank consists of attracting deposits from the general public and investing those funds, together with funds generated from operations and from principal and interest payments on loans, mainly in commercial loans, commercial and residential real estate loans, consumer loans, and residential and commercial construction loans. The primary source of revenue is interest income from earning assets, namely loans and securities.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.